Human Papilloma VirusNCT04023955
Promoting HPV Vaccine Through Twitter
An observational study of Human Papilloma Virus, run by Tufts University.
Trial summary
This study assessed the feasibility of implementing a one-month Twitter campaign to promote knowledge about the human papillomavirus (HPV) vaccine among low-income women living in public housing. Read more about this study
- Who is it for?
- Ages 18 to 26 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Human Papilloma Virus
- What is being tested?
- Type of treatment
- Vaccines, Lifestyle or therapy programme
- How many people
- 48 participants
- Where
- No sites listed yet
- Study dates
- 1 Jun 2016to 10 Jun 2018
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 26 years
- Women only
- Healthy volunteers accepted
- Adult
Study population: Women residing in public housing Ages18-26 years No history of cervical cancer
Who may be able to join
- English-speaking women Age18-26 years Residents of public housing in two Massachusetts cities
Who cannot join
None listed.
About this study
Official title: Feasibility of a Twitter Campaign to Promote HPV Vaccine Uptake Among Racially/Ethnically Diverse Young Adult Women Living in Public Housing
This study assessed the feasibility of implementing a one-month Twitter campaign to promote knowledge about the human papillomavirus (HPV) vaccine among low-income women living in public housing.
Read the detailed description
Investigators recruited a convenience sample (n=35) of women ages 18-26 years who resided in public housing in Massachusetts. Investigators assessed the feasibility and acceptability of the campaign. Online assessed changes in HPV knowledge, attitudes, and vaccine intentions before and after the campaign.
- Conditions
- Human Papilloma Virus
- Being tested
- Keywords
- vaccination, feasibility, public housing
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
TwitterBehavioural
Participants received a daily tweet over a period of one-month with educational messages about HPV vaccine and cervical cancer
| Study group | Role | What they receive |
|---|---|---|
| Intervention | Twitter messages delivered over 1 month period Receives: Behavioral: Twitter |
What is being measured
The primary outcome is the main question the study is designed to answer.
Measure of Humanpapilloma VirusVaccine Knowledge
13 items that assess knowledge about HPV, the HPV vaccine, and cervical cancer; HPV and cervical cancer risk factors and HPV transmission. Score from 0-100% with higher scores indicating greater knowledge
Measured: 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Jul 2019
- Study start1 Jun 2016
- Primary completion10 Jun 2018
- Study completion10 Jun 2018
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Human Papilloma VirusStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 48 participants (actual)
Sponsor and investigators
- Lead sponsor
- Tufts University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Jennifer Allen, Tufts University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04023955
- Sponsor's protocol ID
- 1603045
- Status last verified
- Aug 2019
- First submitted
- 1 Jul 2019
- Last updated
- 4 Sep 2019
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 4 Sep 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Feasibility of a Twitter Campaign to Promote HPV Vaccine Uptake Among Racially/Ethnically Diverse Young Adult Women Living in Public Housing
- ClinicalTrials.gov ID
- NCT04023955
- Acronym / sponsor ID
- 1603045
- Conditions
- Human Papilloma Virus
- Keywords
- vaccination, feasibility, public housing
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 48 participants (actual)
- Lead sponsor
- Tufts UniversityUniversity, hospital or other
- Study start
- 1 Jun 2016 (actual)
- Primary completion
- 10 Jun 2018 (actual)
- Study completion
- 10 Jun 2018 (actual)
- First posted
- 18 Jul 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study assessed the feasibility of implementing a one-month Twitter campaign to promote knowledge about the human papillomavirus (HPV) vaccine among low-income women living in public housing.
Detailed description
Investigators recruited a convenience sample (n=35) of women ages 18-26 years who resided in public housing in Massachusetts. Investigators assessed the feasibility and acceptability of the campaign. Online assessed changes in HPV knowledge, attitudes, and vaccine intentions before and after the campaign.
Study design
- Observational model
- Case only
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Intervention | – | Behavioral: TwitterTwitter messages delivered over 1 month period |
Who may qualify
- Ages
- 18 to 26 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult
- Study population
- Women residing in public housing Ages18-26 years No history of cervical cancer
Key inclusion criteria (1 listed)
- English-speaking women Age18-26 years Residents of public housing in two Massachusetts cities
Key exclusion criteria (0 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| TwitterParticipants received a daily tweet over a period of one-month with educational messages about HPV vaccine and cervical cancer | Behavioural | Intervention |
Primary outcome
Measure of Humanpapilloma VirusVaccine Knowledge
Time frame: 3 months
13 items that assess knowledge about HPV, the HPV vaccine, and cervical cancer; HPV and cervical cancer risk factors and HPV transmission. Score from 0-100% with higher scores indicating greater knowledge
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Sep 2019.
- Individual participant dataSharing planned: No
Related trials for Human Papilloma Virus
Active, not recruitingPhase 3
Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)
Common Warts, Common Warts (Verruca Vulgaris)
RecruitingPhase 3
Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris)
Common Warts (Verruca Vulgaris), Common Warts
Recruiting
Developing and Implementing HPV SCREENED
Cervical Cancer Screening, Human Papilloma Virus
RecruitingPhase 2
A Study of the Preliminary Efficacy of DARE-HPV to Treat High-risk Persistent Human Papillomavirus (hrHPV)
Human Papilloma Virus (HPV), High-risk Human Papillomavirus Infection
Not yet recruitingPhase 2
Safety and Systemic Exposure of YCANTH (VP-102) in Subjects With Common Warts (Verruca Vulgaris) (COVE-5)
Common Warts, Common Warts (Verruca Vulgaris)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
An observational study of Human Papilloma Virus, run by Tufts University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 4 Sep 2019. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Measure of Humanpapilloma VirusVaccine Knowledge (time frame: 3 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Sep 2019; AzTrials last refreshed its copy on 27 Oct 2026.